Publication of clinical trial

Deltex Medical Group PLC
04 October 2006


                                                                 

                            Deltex Medical Group plc

 Publication of clinical trial using SupraQ(TM) to compare different approaches 
          to epidural anaesthesia in women undergoing caesarean delivery


4 October 2006 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), 
the UK's leading haemodynamic monitoring company, today announces the 
publication of a randomised, controlled clinical trial comparing two approaches 
to epidural anaesthesia in women undergoing elective caesarean delivery. The 
results were published in the medical journal Anesthesia and Analgesia.

Doctors at the Royal Free Hospital in London, under the leadership of Dr Roshan
Fernando, used Deltex Medical's SupraQ monitor to look at haemodynamic stability
during epidural anaesthesia. The SupraQ was chosen because it is wholly
non-invasive and can provide doctors with information about a patient's
haemodynamic status that previously was only available using invasive monitoring
technology. These more invasive systems were felt to pose too great a risk of
complications to be appropriate for use in these healthy patients. Traditional
measures of haemodynamic status like blood pressure and heart rate are
insufficiently sensitive to detect changes in haemodynamic status early enough
to be of value.

This trial is the first to compare the changes in haemodynamic status caused by
these two methods of delivering epidural anaesthesia.

The aim of the trial was to test the impact of the different approaches to
anaesthetic delivery on haemodynamic stability in order to better inform medical
research and the development of improved anaesthetic protocols for patients
undergoing caesarean delivery.

Dr Fernando commented:

'The results of this trial will prove invaluable in improving the management of
high-risk patients presenting for caesarean section, such as those with
significant cardiovascular disease.'

Deltex Medical's chief executive, Andy Hill, commented:

'This trial confirms the need and potential for a wholly non-invasive
haemodynamic monitor that can provide doctors with the same reliable,
high-quality data, in real-time, as the CardioQ. The SupraQ allowed Dr Fernando
and his collaborators to measure changes in key indicators of cardiac function
as they happened, something that more invasive and potentially risky
alternatives cannot do.'


For further information, please contact:

Deltex Medical Group plc        01243 774 837
Nigel Keen, Nigel Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Gavin Anderson & Company        020 7554 1400
Deborah Walter
Marie Cairney
Jodie Reilly

Charles Stanley Securities      020 7149 6457
Philip Davies


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange